Healthy volunteers were enrolled in the study..
Conditions
Interventions
Intervention 1: receives an Iranian drug and blood concentrations are obtained at specific time intervals. In the second series, this group receives the brand name drug. Intervention 2: Intervention g
Sponsors
Alhavi Pharmaceutical Company
Eligibility
Sex/Gender
Male
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Good general health (liver, heart, and kidneys). Body mass index (18-28). Informed consent Ages range (18-55 years)
Exclusion criteria
Exclusion criteria: History of allergic or adverse reaction to Rimegepant or any similar product. Addiction to cigarettes, alcohol, or any type of drug Volunteers with a history of chronic diseases such as high blood pressure or high blood lipids, etc. who have taken medication in the past two months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Drug Plasma Concentration. Timepoint: 0, 0.5? 1? 1.5? 2? 2.5? 3? 3.5? 4? 5? 6? 12? 24, 45, 48 hour. Method of measurement: Liquid chromatography with dual mass spectrometer (LC/M?S/MS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaeed Ghanbarzadeh
Tabriz University of Medical Sciences
Outcome results
None listed